Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.31 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18085478 | 0.94 | TSHR (0.53) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL2307153 | 0.91 | MEN1 (0.73) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL13625481 | 0.91 | MEN1 (0.73) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL12595181 | 0.91 | MEN1 (0.73) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL22144196 | 0.91 | MEN1 (0.73) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL29861938 | 0.88 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL15384217 | 0.88 | MEN1 (0.79) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL168645 | 0.88 | — | — | |
| SCHEMBL16450523 | 0.88 | MEN1 (0.79) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL18306668 | 0.88 | MEN1 (0.79) | MEN1KMT2ATSHRMAPK1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415510-B2 | Synthesis of a PEG-6 moiety from commercial low-cost chemicals | GE HEALTHCARE LIMITED (GB) | 2013-04-09 | — | — | US | claimed |
| EP-2268609-A1 | SYNTHESIS OF A PEG-6 MOIETY FROM COMMERCIAL LOW-COST CHEMICALS | GE Healthcare Limited (GB) | 2011-01-05 | — | — | EP | claimed |
| US-20100324264-A1 | SYNTHESIS OF A PEG-6 MOIETY FROM COMMERCIAL LOW-COST CHEMICALS | GE HEALTHCARE LIMITED (GB) | 2010-12-23 | — | — | US | claimed |
| WO-2009108484-A1 | SYNTHESIS OF A PEG-6 MOIETY FROM COMMERCIAL LOW-COST CHEMICALS | GE HEALTHCARE LIMITED (GB) | 2009-09-03 | — | — | WO | claimed |
| US-8415510-B2 | Synthesis of a PEG-6 moiety from commercial low-cost chemicals | GE HEALTHCARE LIMITED (GB) | 2013-04-09 | — | — | US | disclosed |
| EP-2268609-B1 | Synthesis of a PEG-6 moiety from commercial low-cost chemicals | GE HEALTHCARE LTD (GB) | 2013-01-30 | — | — | EP | disclosed |
| CN-102015632-A | Synthesis of a PEG-6 moiety from commercial low-cost chemicals | GE HEALTHCARE LTD | 2011-04-13 | — | — | CN | disclosed |
| EP-2268609-A1 | SYNTHESIS OF A PEG-6 MOIETY FROM COMMERCIAL LOW-COST CHEMICALS | GE Healthcare Limited (GB) | 2011-01-05 | — | — | EP | disclosed |
| US-20100324264-A1 | SYNTHESIS OF A PEG-6 MOIETY FROM COMMERCIAL LOW-COST CHEMICALS | GE HEALTHCARE LIMITED (GB) | 2010-12-23 | — | — | US | disclosed |
| WO-2009108484-A1 | SYNTHESIS OF A PEG-6 MOIETY FROM COMMERCIAL LOW-COST CHEMICALS | GE HEALTHCARE LIMITED (GB) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324264-A1 | SYNTHESIS OF A PEG-6 MOIETY FROM COMMERCIAL LOW-COST CHEMICALS | GAS6, LNPEP, BMP6 | MEN1 2158/4885KMT2A 1884/4885TSHR 2840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.